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ABSTRACT 
Type-2 diabetes (T2D) is characterized by hyperglycemia and hyperlipidemia, resulting 
in impaired insulin production and insulin resistance in peripheral tissues. Several 
studies have demonstrated an association between diabetes and central nervous system 
complications such as stroke and Alzheimer’s disease. Due to the fact that T2D is one 
of the fastest growing chronic illnesses, there is an urgent need to improve our 
knowledge on the pathogenic mechanisms to why diabetes leads to brain complications 
as well as to identify novel drugable targets for therapeutic use. 
Project 1: studies I-II 
Pre-clinical studies have shown that adult neurogenesis is impaired in diabetic animal 
models. We hypothesized that diabetes leading to neurogenesis impairment plays a role 
in the development of neurological complications. If so, normalizing neurogenesis in 
diabetes/obesity could be therapeutically useful in counteracting neurological 
dysfunction. The aim of studies I-II was to establish an in vitro system where to study 
the effect of a diabetic milieu on adult neurogenesis. Furthermore, we determined the 
potential role of pituitary adenylate cyclase-activating polypeptide (PACAP) and 
galanin to protect adult neural stem cells (NSCs) from these diabetic-like conditions. 
Moreover, we determined whether apoptosis and the unfolded protein response (UPR) 
were induced by diabetic-like conditions and whether their regulation was involved in 
the PACAP/galanin-mediated protective effect. Finally, we studied the potential   
regulation of PACAP and galanin receptors in NSCs in response to diabetic-like 
conditions in vitro and ex vivo.   
The viability of NSCs isolated from the mouse brain subventricular zone (SVZ) was 
assessed in presence of a diabetic milieu, as mimicked by high palmitate and glucose, 
which characterize diabetic glucolipotoxicity. The results show that high palmitate and 
glucose impair NSC viability in correlation to increased apoptosis (Bcl-2, cleaved 
caspase-3) and UPR signaling (CHOP, BIP, XBP1, JNK phosphorylation). We also 
show that PACAP and galanin counteract glucolipotoxicity via PAC1 receptor and 
GalR3 activation, respectively. Furthermore, we also report that PACAP and galanin 
receptors are regulated by diabetes in NSCs in vitro and in the SVZ ex vivo.  
 
Project 2: study III 
T2D is a strong risk factor for stroke and no therapy based on neuroprotection is 
currently available. Exendin-4 (Ex-4) is a glucagon-like peptide-1 receptor (GLP-1R) 
agonist in clinical use for the treatment of T2D, which has also been shown to mediate 
neuroprotection against stroke pre-clinically. However, the applicability of a therapy 
based on Ex-4 has not been investigated in a pre-clinical setting with clinical relevance.  
The aim of this study was to determine the potential efficacy of Ex-4 against stroke in 
T2D rats by using a drug administration paradigm and a dose that mimics a diabetic 
patient on Ex-4 therapy. Moreover, we investigated inflammation and neurogenesis as 
potential cellular mechanisms at the basis of Ex-4 efficacy. T2D Goto-Kakizaki (GK) 
rats were treated peripherally for 4 weeks with daily clinical doses of Ex-4 (0.1, 1, 5 
!g/kg body weight) before inducing stroke by transient middle cerebral artery 
occlusion. The Ex-4 treatment was continued for 2-4 weeks thereafter. The severity of 
ischemic damage was measured by evaluation of stroke volume and by stereological 
counting of neurons in the striatum and cortex. Evaluation of stroke-induced 
inflammation, stem cell proliferation and neurogenesis was also quantitatively assessed 
by immunohistochemistry. We show that peripheral administration of Ex-4 counteracts 
  
ischemic brain damage in T2D GK rats. The results also show that Ex-4 decreased 
microglia infiltration and increased stroke-induced neural stem cell proliferation and 
neuroblast formation, while stroke-induced neurogenesis was not affected by Ex-4 
treatment. 
 
Together, our data in project 1 show that we have established an in vitro assay where to 
study the molecular mechanism on how diabetes impact adult neurogenesis. 
Furthermore, our results show that this assay has the potential to be developed into a 
screening platform for the identification of molecules that can regulate adult 
neurogenesis under diabetes. In project 2, we show neuroprotective efficacy against 
stroke by Ex-4 in a T2D rat model, by using a pre-clinical setting with clinical 
relevance. Ex-4 is an anti-diabetic drug in clinical use that has been reported to show 
limited side effects. Thus, at least in theory stroke patients should be able to easily 
receive this treatment, probably with minimal risks. !
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INTRODUCTION 
1. Diabetes 
Diabetes mellitus is a complex metabolic disorder mainly characterized by chronic 
hyperglycemia and later associated with dysfunction or failure of various organs (1). 
According to the World Health Organization (WHO), diabetes is one of the most 
prevalent and fastest growing chronic illnesses, globally affecting more than 347 
million people worldwide. Cardiovascular diseases (CVD) accounts for 50-80 % of 
deaths in people with diabetes, a number expected to rise by more than 50 % in the next 
10 years. For these reasons, diabetes has become a major cause of premature illness and 
death in most countries and is predicted to become the seventh leading cause of death 
in the world by 2030. Moreover, diabetes accounted for ~ 12 % of total health-care 
expenditure in the world in 2010 (2), and it’s estimated that the global health-care costs 
to treat and prevent diabetes and its complications to increase from International 
Dollars (ID) 218 billion in 2010 to ID 561 billion in 2030 (3).  
 
There are two main forms of diabetes, classified by etiology: type 1 diabetes (T1D) and 
type 2 diabetes (T2D).  
 
1.1 Type 1 diabetes 
T1D most often develops in childhood or adolescence but can occur at any age (1). 
T1D’s characterization is based on a cell-mediated autoimmune disease causing 
destruction of pancreatic $-cells leading to absolute or near total loss of insulin 
production, to such a degree that insulin therapy becomes necessary (4). In the much 
less common T1Db, there is also $-cell destruction; however, on a non-autoimmune 
base. Several studies have suggested that various pro-inflammatory cytokines, such as 
interleukin (IL)-1, IL-1$ and tumor necrosis factor # (TNF#), interferon gamma (IFN") 
and reactive oxygen species (ROS), such as superoxide radicals, hydrogen peroxide and 
nitric oxide, may play important role in pancreatic $-cell destruction (5, 6). Certain 
viral infections and human leukocyte antigen (HLA) subtypes have also been connected 
to T1D (7, 8). 
 
1.2 Type 2 diabetes 
T2D accounts for 90-95 % of diabetic patients (9). Previously a disease of middle-
aged and older adults, T2D is rapidly increasing among young people. The main 
causes of the syndrome appear to be multiple and include obesity (especially 
abdominal obesity), physical inactivity, insulin resistance, aging, and a genetic 
predisposition (10, 11). T2D is characterized by insulin resistance leading to 
progressive decline in functional $-cell mass and impaired insulin production (12). 
Normally, $-cells compensate for insulin resistance by increasing insulin secretion 
and $-cell mass. In addition, along the progression of T2D, pancreatic $-cells initially 
go through a proliferative state in order to compensate for insulin resistance in 
peripheral tissues (11). Later, higher levels of glucose and free fatty acid (FFA) 
(glucotoxicity and lipotoxicity) create an unnatural environment; these events are 
believed to trigger $-cell apoptosis which results in a decreased $-cell mass, relative 
insulin deficiency and the onset of overt diabetes symptoms (13, 14). However, this is 
a slow and insidious process that may take 15-20 years until diabetes eventually is 
diagnosed, under which time organ damage occurs. It is estimated that, by the time of 
diagnosis, 50 % of $-cell mass is lost. Additionally, ROS have been shown to trigger 
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the progression of islet dysfunction (5). T2D is diagnosed by fasting plasma glucose 
levels >7 mmol/l on two different occasions, or by plasma glucose concentration 
>11.1 mmol/l 2 hours following an oral glucose tolerance test, or a random plasma 
glucose level exceeding 11.1 mmol/l combined with typical symptoms, according to 
the criteria by the WHO.  
The pathophysiology of T2D involves defects in several organs, i.e. liver, pancreas, 
adipose and skeletal muscle tissue that “conspire” together to produce abnormal 
glucose and lipid metabolism. T2D often co-exists with other disorders, including 
obesity, hypertension and dyslipidemia (a.k.a. the metabolic syndrome), which may 
contribute to the severity of its complications. It has been well documented that people 
with diabetes suffer from peripheral neuropathy (15). However, substantial 
epidemiological evidence suggests that both T1D and T2D are also strongly associated 
with cognitive impairment (16-19).  
 
2. T2D and CNS complications 
In addition to the better characterized peripheral neuropathies, several studies have 
demonstrated an association between diabetes and central nervous system (CNS) 
complications, such as stroke, dementia, Alzheimer’s disease (AD) and Parkinson’s 
disease (PD) (20-22). However, the molecular and cellular mechanisms at the basis of 
why this occurs have not yet been fully understood. T2D is a complex disease that 
extends beyond its dysfunctional glucose regulation. People with T2D generally have a 
“metabolic syndrome” (23), which comprises a cluster of abnormalities that occur as a 
result of disturbances in multiple metabolic pathways, such as hyperinsulinemia, insulin 
resistance, hyperglycemia, hypoglycemia, dyslipidemia, hypertension, vascular 
dysfunction, pro-inflammatory conditions (oxidative stress) and obesity. These 
conditions may play a role in the development of CNS complications in diabetes (24, 
25). 
 
2.1 Dementia 
Significant strides in the treatment of T2D have improved the life expectancy of T2D 
patients. However, the improved longevity has increased the risk of developing 
geriatric health complications prematurely, including cognitive impairment and 
dementia (26, 27). Compared to the general population, the risk of developing dementia 
is 1.5-2.5 times higher in people with T2D (28). Although controlling some of the 
diabetes parameters, such as hypertension, has shown promising results (29), currently 
there is no effective treatment available.  Moreover, diabetes-related factors such as the 
age of onset of diabetes, diabetes duration, type of mechanism of action of anti-diabetic 
medications, presence of other diabetes-related complications, comorbidities and 
diabetes-specific complications could interact with the clinical expression and 
neuropathology of dementia, as well as with the rate of cognitive decline (30). 
However, several mechanisms have been proposed to explain the association between 
diabetes and dementia, such as brain vascular lesion (31), recurrent hypoglycemia (32), 
advanced glycation end products (AGE) (33), inflammation (34), oxidative stress (35), 
competition of insulin and $-amyloid in the insulin-degrading enzyme (36) and insulin 
resistance (37).  
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2.1.1 Alzheimer’s disease (AD)   
AD is the most common neurodegenerative disease characterized by chronic dementia 
with around 50-80 % of all dementia cases (38-40). The most common risk factor is 
increased age (41). Currently affecting around 36 million people worldwide with a 
global cost of $600 billion in 2010, AD is the biggest unmet medical need in neurology. 
Current drugs improve symptoms, but do not have profound disease-modifying effects; 
this is mainly due to un-elucidated etiology of the disease (42). AD is characterized by 
progressive memory deficiency and neuronal loss (43). The main basic pathological 
processes affecting the disease are deposition of senile plaques (insoluble fibrous 
protein aggregations) and neurofibrillary tangles (NFTs), characterized primarily by 
hyperphosphorylated tau protein in the frontal cortex (21). Familial AD is caused by 
genetic factors, such as gene mutation of presenilin 1 (PSEN1), presenilin 2 (PSEN2), 
amyloid precursor protein (APP), and the apolipoprotein E4 (44). Yet, the late-onset 
AD might be caused by environmental and/or lifestyle factors (45). Epidemiological 
studies of patient data sets have clearly identified T2D as a risk factor for developing 
AD (25, 32, 46, 47).  
 
Hyperglycemia, increased oxidative stress levels, alterations of microvasculature and 
not least recurrent hypoglycemia following T2D treatments are the main players at the 
basis of T2D that could induce AD (40), but also comorbid conditions such as 
hypertension, small brain infarcts, dyslipidemia and obesity (39). An important role 
connecting diabetes and decreased cognitive function is insulin resistance (48), where a 
compensatory chronic elevation of circulating insulin may exert a negative influence on 
memory and other cognitive functions (49). While it is generally agreed that glucose 
uptake by the brain does not require insulin, insulin may serve other functions in the 
CNS. In fact, T2D has been associated with impaired learning in both animal and 
human studies (50). Moreover, it has been shown that even non-diabetics who are 
insulin resistant show an increase risk to develop dementia/AD (21, 30). 
Desensitization of insulin receptors has been observed in the brains of AD patients and 
appears to directly contribute to the development of AD (51, 52). A major component 
of NFTs is hyperphosphorylated tau; cleaved tau is detected in brains of patients with 
AD (40). Interestingly, in mouse models of diabetes, increased tau phosphorylation has 
been shown (53). Moreover, insulin may affect tau phosphorylation (54) where a study 
has shown an increase of tau phosphorylation in the CNS of conditional knockout 
mouse for the insulin receptor (55). Therefore, some current therapeutical strategies in 
order to prevent or treat AD, aim to normalize insulin signaling in the brain (49). 
 
2.2 Parkinson’s disease (PD) 
PD is the second most common neurodegenerative disease, affecting 1-2 % of humans 
aged 60 years and older and it’s characterized by a loss of dopaminergic neurons in the 
substantia nigra pars companda (SNpc) region of the brain, with display of 
intracytoplasmic Lewy bodies that consist of aggregated filamentous #-synuclein. The 
clinical symptoms of PD patients are muscle rigidity, bradykinesia, resting tremor and 
postural instability (56). These symptoms are caused by dopamine deficiency in the 
striatum due to the degeneration in the SNpc. Depression and dementia may also occur 
(57, 58). Diabetes and PD patients share disruption in common mechanistic pathways. 
For example, 60 % of the PD patients have impaired insulin signaling and are glucose 
intolerant (59), where recent studies have shown insulin resistance in 62 % of PD 
patients with dementia, of which 30 % were glucose intolerant (60). In addition, a study 
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showed diabetes associated with parkinsonian symptoms (61). Moreover, recent studies 
show PD and diabetes share genetic susceptibility that put individuals at risk for both 
diseases (62, 63). Interestingly, heavy metal exposure is associated with islet 
dysfunction and disease progression in both PD and diabetes (59, 64). Additionally, 
mitochondrial dysfunction, endoplasmic reticulum (ER) stress and inflammation play a 
role in the etiology and progression of both diseases (65-67). Therefore, many factors 
that put individuals at risk of PD also put them at risk for diabetes. However, these 
findings have been disputed (68) and therefore more studies are required to demonstrate 
if there is a link between PD and T2D.        
 
2.3 Stroke  
Stroke cause long-term disability and mortality in the Western population. This has led 
to a large financial burden on the health systems worldwide (69). There are two types 
of strokes: ischemic, which accounts for 85% of stroke cases, and hemorrhagic. 
Hemorrhages are caused by the rupture of blood vessels, and hypertension is the 
primary risk factor (70, 71). Ischemic stroke can be further subdivided into thrombotic 
and embolic stroke (70). Thrombotic stroke occurs when a blood clot (thrombus) 
blocks the blood flow of a specific brain area. A thrombus may form in an artery 
affected by atherosclerosis. Embolic stroke occurs when a piece of clot (embolus) 
breaks loose, for instance from the heart if there is atrial fibrillation and it’s carried 
through the bloodstream to the brain, where large vessels branch off into small vessels. 
When it reaches a point where it cannot travel further, blood supply to the part of the 
brain is cut off (69). The reduction of blood flow can lead to insufficient supply of 
oxygen and glucose to the tissue, causing ATP depletion, ionic homeostasis alterations, 
inflammation, release of multiple cytokines and abnormal release of neurotransmitters, 
as a consequence leading to energy failure and mitochondrial dysfunction, and 
eventually cell death (72). 
 
There are several risk factors associated with stroke, e.g. hypertension, arterial 
fibrillation, smoking, hyperlipidemia and diabetes (69). T2D is an independent risk 
factor for stroke, particularly ischemic stroke, where studies have reported a 2-6 fold 
increase risk for stroke in diabetic patients versus those without (20). Also, stroke 
typically occurs prematurely in diabetic patients. In addition, T2D also doubles the risk 
of stroke recurrence, which generally shows a worse functional outcome than the first 
stroke (20, 73), increasing the mortality rate (74). Moreover, diabetes-associated risk 
factors for stroke do not only include hyperglycemia or vascular risk factors (e.g. 
hypertension, dyslipidemia), but also genetic, demographic and lifestyle factors can 
contribute (74). Even after these risk factors have been adjusted with conventional 
therapies, a doubling of ischemic stroke cases is still seen in T2D patients compared 
with non-diabetic individuals (73). The risk of stroke in T2D patients arises already in 
pre-diabetic stages, where insulin resistance is a strong risk factor for stroke (73). In 
addition, amounts of HbA1c levels have been proposed as a measure of risk for stroke 
occurrence in pre-diabetic patients, where a level greater than 42 mmol/mol (6 %) can 
increase the risk of stroke 2-3 times compared to normoglycemic individuals (75).     
 
2.3.1 GLP-1R, a neuroprotective target for the potential treatment of stroke in T2D 
The major limitation in the development of neuroprotective therapeutic strategies 
against stroke is contingent upon how quickly neurons die (“time is brain”). Because of 
this, several pre-clinically successful candidate drugs with neuroprotective properties 
(used before or few minutes after stroke in rodents) have failed in clinical trials once 
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administered to patients few hours after stroke (76, 77). Thrombolytic treatment with 
recombinant tissue plasminogen activator (r-TPA) is the only method that is partially 
effective against stroke if given within 3-4 hours from the onset of stroke (78). 
However, the majority of the patients do not reach the hospital in time or have counter-
indications to receive this treatment (79). In addition, r-TPA has been associated with 
increased risk of hemorrhagic transformation and r-TPA is performed even less 
frequently in diabetic patients with stroke, since elevated blood glucose and diabetes 
are associated with increased risk of intracerebral hemorrhages after r-TPA use (EU 
Stroke Guidelines 2009) (80, 81). While it is still unclear if glucose lowering can be 
beneficial against stroke, it is well understood that hypoglycemic events (that can result 
from glucose lowering treatments) should be avoided in T2D patients suffering stroke 
(74) and therefore insulin might not the best drug in that respect. An ideal therapy for 
the treatment of stroke in T2D would be a drug that is effective in rapidly normalizing 
glycemia (devoid of propensity for hypoglycemic side effects) in combination with a 
neuroprotective property.  
 
Glucagon-like peptide-1 (GLP-1) is an insulinotropic hormone and member of the 
proglucagon-derived peptide family, which is secreted from enteroendocrine L-cells 
upon nutrient ingestion (82). GLP-1 exerts its physiological effects following the 
binding to its receptor (GLP-1R), a 463-amino acid, G-protein-coupled receptor 
(GPCR). The signal transduction pathways of GLP-1 and its analogues in the 
pancreatic $-cell are mediated through adenylate cyclase (AC) and the cAMP/PKA 
pathways to potentiate glucose-induced closure of ATP-sensitive K+ channels, thereby 
generating cellular depolarization, activation of voltage-dependent Ca2+ channels 
(VDCCs) and influx of Ca2+ that sets in motion insulin exocytosis (83). GLP-1 has 
multifunctional effects according to its sites of synthesis and release (84). In addition to 
stimulate glucose-dependent insulin secretion, GLP-1 is associated with a number of 
cellular survival and plasticity effects, including $–cell islet neogenesis, protection 
against apoptosis (85), cardioprotective (86) and anti-inflammatory effects (87).  
Exenatide [synthetic exendin-4 (Ex-4)] is a stable GLP-1 analogue isolated from the 
saliva of the “Gila monster” lizard (88).  It is resistant to degradation and is approved in 
both Europe and the U.S. for the clinical treatment of T2D (82).    
 
Although the GLP-1 receptor is pre-dominantly located in the pancreatic islets, in the 
CNS GLP-1 is synthesized largely in the brainstem and transported along axonal 
networks to diverse CNS regions. Several studies have shown its expression in the 
rodent (89) and human (90) brain, e.g. in the hypothalamus, neocortex, brainstem and 
the hippocampus, where early findings showed its role in food intake regulation (91). 
Recently, a study showed that small amounts of GLP-1 are also produced by the 
microglia cells in the brain (92). Moreover, GLP-1 and Ex-4 can cross the blood-brain 
barrier (93). Studies have shown that exogenous Ex-4/GLP-1 also acts as a 
neuroprotectant in models of AD, PD (87, 94) and stroke, where intracerebroventricular 
administration of Ex-4 15 min before stroke reduced ischemic damage in mice (95). 
Additionally, intraperitoneal injection of Ex-4 2 hours before ischemia and 1 hour after 
reperfusion protected hippocampal CA1 neurons (96). Ex-4 has also shown neurogenic 
properties (97), enhancing synaptic plasticity and improve different forms of learning 
(98).  
 
Although the effects of GLP-1R activation in the brain are promising, the field is still in 
its infancy and more research is needed to understand the mechanisms behind its action 
 6 
and whether GLP-1R activation in diabetes could promote beneficial effects in the 
CNS. 
 
2.4 Endoplasmic reticulum stress: a mechanism at the basis of CNS complications in 
T2D?  
Emerging evidence suggests that ER stress may play a pivotal role in the development 
and pathology of many neurodegenerative diseases (66, 67, 99). In recent years, ER 
stress has been implicated in metabolic disorders, such as obesity, T2D and 
atherosclerosis (100, 101) In response to such conditions, cells initiate pro-survival 
signaling pathways collectively known as the unfolded protein response (UPR) (101, 
102), which consists of three signaling pathways each controlled by a specific protein, 
viz. CHOP, GADD34, Grp78/BIP and spliced XBP1. Activation of the UPR pathways 
is often used as an indicator of ER stress (103). The UPR normally serves to alleviate 
ER stress by inhibiting general protein translation, increasing folding capacity and 
promoting degradation of misfolded proteins. Normally, the efforts mounted by the 
UPR restore the intra-organelle milieu and are therefore cytoprotective (104). If these 
actions fail to rescue the cells from ER stress, then apoptosis can occur (105). It is not 
clear exactly when and how a cell “decides” between pro-survival and pro-apoptotic 
signaling, nor is the mechanism behind ER stress-induced apoptosis fully elucidated but 
it includes reduced Bcl-2 expression. Excessive activity in the UPR does, however, 
converge in the mitochondria and results in opening of the permeability transition pore, 
loss of mitochondrial membrane potential, leakage of cytochrome c, formation of the 
apoptosome and activation of caspases (105). Moreover, elevated levels of circulating 
fatty acids and hyperglycemia increase the production of ROS (13, 106), and it may 
lead to cellular apoptosis. The mitogen-activated protein kinase (MAPK) signaling 
cascade transduces this apoptotic message. Two mammalian MAPKs, c-Jun N-terminal 
kinase (JNK) and p38 MAPK are known to be activated by various environmental 
stressors and inflammation (107). Apoptosis signal-regulating kinase (ASK) 1 can 
activate the JNK and p38 pathways, and thus tightly regulate the kinase activity of 
ASK1(108). 
 
3. Adult neurogenesis 
“Once development was ended, the fonts of growth and regeneration of the axons and 
the dendrites dried up irrevocably. In the adult centers, the nerve paths are something 
fixed, and immutable: everything may die, nothing may be regenerated.”- Santiago 
Ramón y Cajal, 1928 
We know today that the generation of new neurons continuously occurs in the adult 
brain in selected regions, namely the subgranular zone of hippocampus and the 
subventricular zone of the lateral ventricle wall (SGZ and SVZ, respectively) (109-
111). Recently, adult neurogenesis was also described in the hypothalamic region 
(112). However, until only a few decades ago, the prevailing idea was that all neurons 
were developed before birth in the human brain and no new neurons were added to the 
CNS in adult life. It was specifically the work of Altman and colleagues in the 1960s 
(113-116) that showed that new neurons were added in the olfactory bulb (OB) and the 
hippocampus of adult rodents, and in 1998 Eriksson and colleagues showed for the first 
time neurogenesis in the adult human brain (117).  
 
Neurogenesis in the hippocampus occurs in the SGZ adjacent to the dentate gyrus 
(DG). The newly born neurons in the SGZ differentiate and integrate into the local 
neural network as granule cells of the DG. In the DG, specialized GFAP-positive 
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astrocyte-like cells express stem cell markers like nestin, Sox2 and Hes5 (118, 119). 
See figure 1 for more detailed description. This area has been extensively studied, 
mainly due to the importance of hippocampus in relation to brain functions such as 
memory (120) and emotional behaviors (121). To date, the specific role of hippocampal 
neurogenesis is still under debate. Nonetheless, this process has been associated with 
learning (122), stress and certain brain disorders, such as depression. Interestingly anti-
depressant therapy has been shown to increase adult DG neurogenesis (123).   
 
Recent studies have indicated adult neurogenesis also in the hypothalamus, a brain area 
responsible for central homeostatic regulation of numerous physiological and 
behavioral functions such as feeding, metabolism, body temperature, sleep, circadian 
rhythms and sexual behavior (124). Among the first studies to describe adult 
neurogenesis in the hypothalamus were a series of experiments in which co-
intraventricular infusion of brain-derived neurothrophic factor (BDNF) and the 
proliferative marker 5-bromo-2'-deoxyuridine (BrdU) led to an increased level of 
BrdU-positive cells co-labeled with the neuronal marker $III-tubulin in the 
parenchymal part of the hypothalamus (125). This was further confirmed by other 
authors who showed differential distribution of hypothalamic neurogenesis between the 
hypothalamic regions (126). Moreover, a high fat diet (HFD) altered regions of the 
hypothalamic neurogenesis (126-128). In addition, recent pre-clinical reports have 
indicated a role of hypothalamic adult neurogenesis in maintaining energy balance in 
response to environmental and physiological insults (129).  
 
In the ventricular zone, NSCs differentiate into cortical neurons during embryonic 
development (130). At development completion, the ventricular zone becomes the SVZ 
of the lateral ventricle where an ependymal layer separates these two regions (72). 
Ependymal cells have been proposed to be the NSCs responsible for SVZ neurogenesis 
(131). However, other studies have refuted this hypothesis, showing that ependymal 
cells are quiescent and do not have NSCs in vitro properties (132, 133). Today we 
know that the forebrain ependymal cells lining in the lateral walls are normally 
quiescent but can give rise to astrocytes and neuroblasts following stroke (134). 
Whether this property can be used for therapeutic purposes remains to be determined. 
In general, it is accepted within the research community that there are three types of 
cells existing in the rodent and human SVZ, type A, B, C cells. The NSCs in SVZ form 
special subpopulation of GFAP-expressing cells (type B) that originate from highly 
proliferative/amplifying cells known as C cells expressing the marker nestin. Type C 
cells differentiate into type A cells or so-called neuroblasts and migrate radially via the 
rostral migratory stream (RMS) towards the OB. It has also been shown that neurons 
born in the SVZ can migrate into the cortical regions in the primate (135). Type A cells 
express beta-3-tubulin, polysialylated neural cellular adhesion molecule, doublecortin 
(DCX) and Dlx-2 transcription factor. Once they have reached the OB, they 
differentiate into different subtypes of mature interneurons, mainly GABAergic granule 
neurons (136). The function of OB neurogenesis is not fully understood; however, 
several studies point towards an important role in olfaction (137, 138). This process has 
been described in humans (139) and, while the number of migrating neuroblasts is high 
during infancy, it decreases dramatically upon ageing (134, 140).  
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Figure 1. Illustration of neurogenesis in the adult 
brain; SVZ and the DG of the hippocampus. There 
are three types of progenitor cells lying adjacent to 
the ependymal cell layer (E) in the SVZ. Type B 
cells are the quiescent GFAP+ cells. They function 
as precursors of rapidly dividing transit-amplifying 
type C cells. The type A cells migrate through the 
rostral migratory stream towards the olfactory bulb. 
In the SGZ, there is a population of type 1 cells that 
are GFAP+ (Sox2+ nestin, and Hes5) quiescent 
NSCs. They co-exist with actively proliferating; 
GFAP+ Sox2+ NSCs the type 2 cells that give rise to 
both astrocytes and neuroblasts. Neuroblasts then 
migrate into the granule cell layer and mature into 
neurons (red cell). Permission from Sandrine Thuret 
and Hindawi Publishing Corporation.  
 
 
3.1 SVZ neurogenesis and CNS disorders 
Adult neurogenesis can be modulated by different factors, e.g. growth factors, peptides 
and neurotransmitters, but also by traumatic brain injuries and neurological diseases 
and disorders, suggesting that this process can play an important role not only under 
physiological but also under pathological conditions (141). For example, studies on 
Huntington disease (HD) animal models and post mortem human tissues have shown 
impairment in the hippocampal stem cell proliferation (130), suggesting an 
involvement of neurogenesis in depression and other mood disturbances that occur in 
up to 50 % of the HD population (142). Moreover, HD is a disease affecting striatum 
and studies both in animals and humans have shown that there is an up-regulation of 
progenitor cells in the HD SVZ, where cells proliferate and migrate towards the injured 
striatum (143, 144).  
Of relevance for this thesis, SVZ proliferation and striatal neurogenesis have been 
extensively documented after stroke both in the rodent (145, 146) and human (147) 
brain. In particular, stem cell proliferation in the SVZ is increased in response to stroke, 
and a small fraction of neuroblasts deviates their migration towards the damaged 
striatal area, away from their normal migratory stream to the OB (146, 148). In the 
striatum they express markers of developing and mature (striatal medium-sized spiny) 
neurons, which have been suggested to play a role in functional recovery (149). 
Whether this is a causal link, rather than a correlation, remains to be determined (150).  
 
Another important observation linking SVZ adult neurogenesis and neurological 
disorders derives from observations in both AD animal models and post mortem tissues 
from the human AD brain. Although different animal models have shown contradictory 
results, a recent study in the human brain showed that SVZ neurogenesis is impaired in 
AD (151). The data were also confirmed recently by employing an animal model where 
the A$ and tau pathologies are reproduced (152). Whether decreased neurogenesis in 
AD plays a role in the development of the disease remains to be determined.  
 
Reduced OB neurogenesis has been observed in PD model animals and resulted in 
impaired odor discrimination, which is also common in PD in human (153, 154). If 
impaired odor discrimination is related to the disease, is still unknown. However, the 
data about SVZ neurogenesis regulation in PD are contradictory since in a PD study in 
human (post mortem analysis) showed a profound increase in the proliferative capacity 
of SVZ (155), whilst another study showed opposite results (156, 157).   
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In conclusion, a large number of studies have shown that adult SVZ neurogenesis is 
regulated in response to brain pathologic states. However, the functional significance of 
SVZ neurogenesis regulation in neurological disorders has yet to be understood.  
 
 
3.2 SVZ neurogenesis and diabetes  
Recent pre-clinical studies have showed impaired adult neurogenesis in diabetes 
[reviewed by Bachor et al. (158)]. One study demonstrated a marked decrease of 
proliferating BrdU-labeled cells both in the SVZ and DG of streptozotocin (STZ)-
treated rats, which develop a type-1 like-diabetes (159). Another study showed a 
significant increase of proliferating neural progenitors in SVZ and DG of a T2D animal 
model, viz. the Goto-Kakizaki (GK) rat (160). However, the survival of the newly 
formed cells rapidly and significantly decreased. One reason could be their lack of 
responsiveness to growth factors, since NSC cultures derived from lean control animals 
formed neurospheres (NS) when exposed to growth factors, whereas the GK rat NSCs 
did not (160). The precise nature of the mechanisms that mediate dysfunction of the 
neurogenic niches in diabetes is unknown. However, the diabetic impact on 
neurogenesis may change according to the magnitude of the metabolic derangement 
(158) and it is also possible that T1D and T2D impose different effects. In addition, 
diabetes can cause chronic inflammation and oxidative stress, which may 
independently promote neuronal death and inhibit neurogenesis (161, 162). In support 
of the hypothesis that impairment of SVZ neurogenesis in diabetes has physiological 
relevance are recent data showing that dysfunctional hippocampal neurogenesis in 
diabetic and obese animal models (163-165) resulted in cognitive impairment (166). 
 
3.2.1 Pharmacological normalization of SVZ neurogenesis for the treatment of diabetic 
CNS complications 
As explained in the chapters above, diabetic patients suffer from several neurological 
disorders at a very high rate and often prematurely. Adult neurogenesis is impaired in 
experimental models of T1D and T2D, as well as in experimental models of CNS 
disorders/diseases, and in post mortem human brain tissues. It remains to be determined 
whether the pharmacological normalization of adult neurogenesis in diabetes can 
decrease the rate of CNS complications. In support of this hypothesis are results 
showing that pharmacological stimulation of adult neurogenesis correlates with 
beneficial effects in  animal models of PD, AD and amyotrophic lateral sclerosis (157). 
Furthermore, a great number of studies on the efficacy of candidate drugs in animal 
models of stroke have correlated improved histological and behavioral recovery with 
increased SVZ/hippocampal neurogenesis (146, 167). Some of the identified factors 
that can regulate neurogenesis are Noggin (168), vascular endothelial growth factors 
(VEGF) (169) and BDNF (170), where intraventricularly infused BDNF increased the 
number of newly born neurons in the OB of the adult rat brain, and moreover promoted 
neuronal migration into other parts of the brain, such as striatum, septum, thalamus and 
hypothalamus. Extrinsic stimuli, such as voluntary exercise, have also shown positive 
results to counteract the decline in neurogenesis in aged animals (171).  
 
3.2.2 PACAP 
The pituitary adenylate cyclase-activating polypeptide (PACAP) (172) is a 38-amino 
acid neuropeptide that is member of the VIP/secretin/glucagon peptide family, also 
including the vasoactive intestinal peptide (VIP) (173). PACAP and VIP share 67 % 
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amino acid sequence. PACAP and VIP are pleiotropic and multifunctional peptides, 
possessing neurotrophic and neuroprotective properties (174-176). They are involved 
in regulating important biological functions in the brain, digestive tract, 
cardiovascular system, airway, reproductive systems, and the immune system (176). 
In addition, studies in vitro and in vivo have shown their role in insulin secretion in 
both rodents and human islets (176-181). PACAP/VIP have three receptor subtypes 
named PAC1, VPAC1 and VPAC2. VIP binds with high affinity to VPAC1 and 
VPAC2 receptors but with lower affinity to the PAC1 receptor. PACAP and VIP 
receptors are both member of the class B (class II) GPCR family (182). PAC1, 
VPAC1 and VPAC2 receptors are coupled to the G#% protein, regulating intracellular 
concentration of cyclic adenosine monophosphate (cAMP) through stimulation of 
AC. PACAP receptor also modulates intracellular calcium and inositol triphosphate 
levels through the phospholipase C pathway (173). PACAP receptors are widely 
distributed in the body and high levels of PAC1 receptors have also been reported in 
neurological disorders such as brain trauma, PD and AD (183-186). PACAP is found 
in the hypothalamic area, pituitary and the adrenal gland (176, 187), while VPAC 
receptors are expressed mainly in the lung, liver, and the testis (178, 188-190). 
Moreover, PAC1 and VPAC1/VPAC2 receptors play critical roles in early 
development of the CNS (190-192). Neuroprotection through PAC1 signaling is well 
documented (193-196) and PAC1 expression levels have been shown to be increased 
in pathological states, such as ischemic brain injury (196-199). However, the 
neuroprotective actions of VPAC1 and VPAC2 have also been reported in 
neurological disorders such as brain trauma, PD and AD (183-186). In addition, 
targeting each of these receptor subtypes has recently been proposed for the treatment 
of multiple sclerosis (200). 
Germane for this thesis, recent data have shown an important role of PACAP in the 
regulation of adult and embryonic neurogenesis, where studies have shown that 
PACAP induces NSC proliferation/survival and self-renewal both in vitro and in vivo 
(201-203).  
 
3.2.3 Galanin 
Galanin is a 28 (mouse) or 30 (human) amino acid peptide with a wide range of 
biological effects. Galanin is involved in metabolism and reproduction (204, 205), 
survival, regeneration (206), cognition (207, 208) nociception (209, 210), but also 
pathological conditions such as AD (211), addiction (212) and epilepsy (213). 
Galanin triggers cellular responses via at least three seven transmembrane GPCRs, 
namely GalR1-R2-R3; coupled via different Gi/G0-proteins to inhibit AC, causing 
hyperpolarization via opening of K+ channels (GalR1/R3) and increase intracellular 
Ca2+ via stimulation of phospholipase C (GalR2) (214, 215). Both GalR1 and GalR2 
are abundantly expressed in the rat brain (216-219). Individual galanin receptors have 
been associated with specific physiological functions. For instance, the activation of 
GalR1 promotes overeating and weight gain (220), while GalR2 activation confers 
neuroprotection (221, 222). The GalR3 expression pattern has a more restricted 
distribution in rodents with transcript levels most abundant in the dorsal raphe 
nucleus (DRN) locus coeruleus (LC), amygdala and the hypothalamus (219, 223). In 
addition, the physiological and pathological role of GalR3 in the brain is less well 
characterized (224, 225). Recent studies have shown the expression of galanin and 
galanin receptor mRNA in neurogenic areas of the adult mouse brain, but also in the 
SVZ and in hippocampal-derived NSCs cultures (226, 227). In addition, a study in 
mice has shown that GalR2 and/or GalR3 activation can regulate NSC differentiation 
(228).  
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AIMS 
The overall goal of this thesis was to identify new potential therapeutic targets for 
the treatment of diabetic brain complications. We addressed this by running two 
projects, one in vitro and one in vivo. 
 
In project 1 we studied the effect of diabetes-like conditions on adult neurogenesis. 
We hypothesized that adult neurogenesis impairment can be an important player 
linking diabetes and its neurological complications. Thus, we aimed to identify 
compounds able to increase the viability of adult NSCs in response to a diabetes-like 
milieu in vitro. The specific aims of the projects were: 
  
1)  To establish an in vitro assay in which to study the effects of stimulated 
hyperglycemia and hyperlipidemia on adult NSCs isolated from the mouse 
SVZ. 
2)  To identify some of the mechanisms by which a diabetes-like state (i.e. 
glucolipotoxicity) negatively impacts adult NSC viability in vitro.  
3)  To determine the putative protective effects of PACAP and galanin on adult 
NSC viability against diabetic glucolipotoxicity in vitro. 
 
In project 2 we studied whether a neuroprotective strategy based on the activation of 
GLP-1R was efficacious against stroke in T2D rats. The specific objective of the 
projects was: 
 
1)  To prove efficacy of the specific GLP-1R agonist Ex-4 against stroke in the 
Goto-Kakizaki (GK) T2D rat model. 
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MATERIALS AND METHODS 
1. In vitro and ex vivo experiments (Project 1: studies I-II) 
1.1 SVZ isolation and primary NSC cultures  
To obtain NSCs from the adult brain, the SVZ of the lateral brain ventricle of adult 
male mice 5 to 7 weeks of age (five C57 BL6/SCA mice in each experiment) was 
micro-dissected by using a micro-dissector scissor  and enzymatically dissociated in 0.5 
mg/ml trypsin, 0.8 mg/ml hyaluronidase and 80 U/ml deoxyribonuclease I (Sigma-
Aldrich; St Louis, MO) in Dulbecco’s modified Eagle’s medium/ F12 (DMEM/F12; 
Gibco, Life Technologies; Sweden) containing B27 supplement (Gibco, Life 
Technologies; Sweden), 4.5 mg/ml glucose, 100 U/ml penicillin, 100 !g/ml 
streptomycin sulfate and 12.5 mM HEPES buffer solution (Invitrogen, Stockholm, 
Sweden). The enzymatic digestion was carried out at 37 oC for 20 min. After a gentle 
trituration with a pipette and mixing, cells were passed through a 70 !m strainer (BD 
Biosciences; Sweden) and pelleted at 1,000 rpm for 12 min. The centrifugation step 
was repeated once more after removing the supernatant by adding fresh cold 
DMEM/F12. The supernatant was then removed, and cells were re-suspended in 
DMEM/F12 supplemented with B27 and 18 ng/ml human epidermal growth factor 
(EGF; R&D systems; Oxon, U.K.). Cells were plated in a 10 cm Petri dish and 
incubated at 37 oC for 7 days in order for NS to develop. After 7 days, the NS were 
collected and centrifuged at 1,000 rpm for 10 min. To obtain NSCs, NS were re-
suspended in 0.5% trypsin/EDTA (Invitrogen; Sweden), incubated at 37 oC for 2 min 
and triturated gently to aid dissociation. After a further 2 min incubation at 37  oC, the 
cell preparation was diluted 1/20 in DMEM/F12 at 37 oC.  NSCs were then pelleted at 
1,000 rpm for 10 min and re-suspended in fresh DMEM/F12 containing 18 ng/ml EGF 
and 16 ng/ml human basic fibroblast growth factor (bFGF; R&D systems; Oxon, U.K.) 
before plating. NSCs were then expanded for 5 days to form new NS before the next 
passage and splitted again. All experiments were performed between passage 2 and 5 
(studies I-II). 
 
1.2 NSC viability assays  
1.2.1 Fatty acid-enriched media  
To mimic a hyperglycemic and hyperlipidemic milieu in vitro, DMEM/F12 (19 mM 
glucose) containing B27 and sodium palmitate 0.1-0.5 mM (Sigma-Aldrich; St Louis, 
MO) was used. In the experiments, cells were maintained in 0.01 ng/ml of EGF. To 
obtain the desired palmitate concentration, the NSC medium was supplemented with 
0.25% BSA (Roche Diagnostics; Mannheim, Germany) before adding the palmitate 
(from a 100 mM palmitate stock solution dissolved in 12.5% EtOH) (studies I-II). All 
groups received the same concentration of vehicle.  
 
1.2.2 ATP assay   
Previous reports have shown that intracellular ATP levels correlate to cell number 
(229). Thus, an assay based on the quantification of ATP was employed to assess NSC 
viability. NSCs were plated as single cells from NS (see above) into 96-well plates 
(Corning B.V. Life Sciences; Amsterdam, Netherlands) at the final concentration of 
50,000 cells/well in DMEM/F12 supplemented with B27 (study I-II).  
PACAP 38 (1-100 nM) (Phoenix Pharmaceuticals; Burlingame, CA), the specific 
PAC1 agonist Maxidilan-4 (Max-4; 30 nM; graciously provided by Dr. R.G. Titus), 
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Bay 55-9837 (500 nM) (VPAC2-specific agonist) or [Ala2,8,9,11,19,22,24,25,27,28]-VIP (1 
!M; VPAC1-specific agonist) (Tocris Biosciences; Bristol, U.K.) were added to NSCs 
15 min before exposing the cells to 0.1-0.5 mM palmitate depending on the 
experiments. The cultures were maintained for 24 hours until NSC viability was 
assessed. In order to study whether NSC viability was increased by PAC1 activation, 
the specific PAC1 antagonist PACAP 6-38 (1 !M; Tocris Biosciences; Bristol, U.K.) 
was added to the cells 5 min before adding PACAP 38 (100 nM) (study I).  
Native galanin (0.1-10 nM; Gal 1-29, Tocris Biosciences; Bristol, U.K.), the GalR2-3 
agonist Gal2-11 (AR-M 1896 0.1-10 nM; Tocris Biosciences, Bristol, U.K.), the 
selective GalR3 antagonist SNAP-3788 (1 !M; KO Key Organics; London, UK), the 
selective GalR2 antagonist M871 (1 !M; kindly given by Prof. Ülo Langel, Stockholm 
University), the ER stress inducer Salubrinal (50 !M; Calbiochem; La Jolla, CA) or 
PACAP 38 (100 nM) were added to NSCs 15 min prior to exposing the cells to the 
desired palmitate concentrations (study II).  
After 24 hours of incubation at 37  oC (5% CO2, 98% humidity), intracellular ATP 
levels were measured using the Cellular ATP Kit HTS according to the manufacturer’s 
instructions (BioThema; Stockholm, Sweden). In these experiments, the effect of each 
treatment at a certain concentration was determined in quadruplicates or octuplicates in 
3-7 different sets of experiments. The experimental design is illustrated in Figure 2 
(studies I-II). 
 
                
 
 
 
 
 
 
 
 
Figure 2. Experimental design of in vitro experiments 
 
1.2.3 MTT assay  
To confirm the cell viability results of the ATP assay, 3-[4,4-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) levels (230) were also measured in some 
experiments. MTT levels were measured using the CellTiter96® non-radioactive cell 
viability assay according to the manufacturer’s instructions (Promega; Madison, WI). 
In these experiments, the effect of each treatment at a certain concentration was 
determined in quadruplicates in 3 different experiments (study I). 
 
1.3 NSC 3H-thymidine incorporation  
 
To measure NSC proliferation in response to PACAP, 3H-thymidine incorporation into 
DNA was assessed. NS were dissociated to a single-cell suspension and plated as single 
cells in 6-well plates (1,000,000 cells/well). PACAP (100 nM) alone or palmitate (0.2 
mM) plus PACAP were added in duplicates and cells incubated at 37 oC for 24 hours 
(study I).  
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To measure NSC proliferation in response to AR-M 1896 (GalR2/R3 agonist), 3H-
thymidine incorporation was also assessed. AR-M 1896 (10 nM) or PACAP (100 nM) 
(serving as positive control) were added in duplicates and cells incubated at 37 oC for 
24 hours (study II).  
 
3H-thymidine (1 !Ci/ml) (Amersham Biosciences; Piscataway, NJ) was present from 
after plating till when the cells were harvested 24 hours later. Cells were harvested and 
radioactivity was measured using a microplate scintillation and luminescence counter 
(Wallac MicroBeta® Trilux; PerkinElmer; Waltham, MA) (study I-II). 
 
1.4 Western blotting experiments for apoptosis and ER stress markers   
To assess whether PACAP/galanin modulate apoptosis and UPR signaling, Western 
blot (WB) experiments were performed. NSCs were plated as single cells and expanded 
in a 10 cm Petri dish with EGF/bFGF (see 1.1) for 3-4 days. When NS were formed, a 
15 minute pre-treatment of PACAP (100 nM) or the equally affinity agonist for 
GalR2/3, ARM18-96 (10 nM) was carried out before exposing the cells to palmitate 
(0.3 mM). NSCs were then incubated for 24 hours. After NS formation, NS were 
harvested, washed twice with PBS, centrifuged at 1,000 rpm and homogenized on ice. 
Samples were clarified by centrifugation. The supernatants were transferred into new 
tubes and the total protein concentration was determined by Lowry protein assay (Bio-
Rad Laboratories: Stockholm, Sweden). Samples were then mixed with reducing SDS-
PAGE sample buffer and boiled for 5 min before performing SDS-PAGE. After 
electrophoresis, proteins were transferred onto polyvinylidene fluoride (PVDF) 
membranes (Bio-Rad Laboratories; Stockholm, Sweden). Immunoblot analyses were 
performed with antibodies against the cleaved form of caspase-3 (1:1,000), 
phosphorylation/total of JNK (1:3,000) (Cell Signaling Technology; Danvers, MA), 
Bcl-2 (1:200) (Abcam; Cambridge, MA) and CHOP (1:2,000) (Santa Cruz, 
Biotechnology; Stockholm, Sweden). Immuno-reactive bands were developed using 
ECL (GE Healthcare; Stockholm, Sweden), imaged with a GelDoc system and 
quantified with Quantity One software (Bio-Rad Laboratories; Stockholm, Sweden). 
After imaging, to verify equal protein loading, the PDVF membranes were stained with 
Coomassie blue (Fermentas; St. Leon-Rot, Germany).  
In all these experiments, the effect of each treatment at a certain concentration was 
determined in single or double samples in 2-5 different set of experiments (study I-II). 
 
1.5 mRNA quantitative expression studies (RT-PCR)   
1.5.1 PAC1, VPAC1, VPAC2, Galanin, GalR1, GalR2, GalR3, CHOP/GADD153, 
BIP/GRP78 
To quantify the mRNAs of galanin and PACAP receptors and ER stress markers from 
NSCs in vitro, we used NSCs grown in EGF/bFGF (see 1.1) at passages 2-4 in 
presence or absence of palmitate (0.3 mM) and/or the different treatments for 24 hours. 
Effects were determined in single samples in 3-6 different sets of experiments. 
In the ex vivo quantitative experiments, tissue from the SVZ of the lateral ventricle (less 
than 1 millimeter of tissue facing the lateral ventricle and including the SVZ) or the 
deeper part of striatum (not including the SVZ) was isolated for analysis (see above). 
Three to twelve brains, isolated from 5 week-old (young-adult pre-diabetic) and 36 
week-old (middle aged diabetic) ob/ob mice plus their cognate lean littermates, were 
pooled in each experiment.  
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Total RNA was extracted using Aurum total RNA-mini kit (Bio-Rad Laboratories; 
Stockholm, Sweden) and the RNA was treated with DNase I (Bio-Rad Laboratories; 
Stockholm, Sweden) to eliminate possible DNA contamination, according to the 
manufacturer’s protocol. Total mRNA was reversely transcribed into cDNA by using 
an iScriptTM cDNA Synthesis Kit (Bio-Rad Laboratories; Stockholm, Sweden). The 
expression levels of mRNAs were measured by SYBR green based quantitative RT-
PCR (iQTM SYBR® Green Supermix; Fermentas; St. Leon-Rot, Germany) using 
mouse-specific primer pairs for PAC1 transcript variant 1, VPAC1 and VPAC2 
(Invitrogen; Stockholm, Sweden) (study I) and mouse-specific primer pairs for 
Galanin, GalR1, GalR2, GalR3, CHOP/GADD153, BIP/GRP78 (Invitrogen; 
Stockholm, Sweden) (study II).  
$-actin was used as an internal standard in all experiments. Reactions were resolved on 
a 1 % agarose gel containing ethidium bromide and the bands were visualized under 
UV light to verify the correct sizes of the amplification products.  
 
1.5.2 Measurement of XBP1 mRNA splicing   
To determine whether diabetic glucolipotoxicity induces UPR signaling, e.g. the IRE1 
pathway, total RNA was isolated and cDNA synthesized from NSCs as described 
above after exposure to palmitate (0.3 mM) for 24 hours. Mouse XBP1 cDNA was 
amplified using iProof Master Mix (Fermentas; St. Leon-Rot, Germany) and XBP1 
primers, flanking the 26 bp splicing site (231), which contains a PstI restriction site 
(CTGCAG). The PCR product was incubated with 1 !l fast digest PstI per reaction 
(Fermentas) for 30 min at 37 oC and the digested product was then separated on a 2 % 
agarose gel and visualized using ethidium bromide. The gel shows one band at 746 bp 
for spliced XBP1 and two bands at 458 and 314 bp for the non-spliced XBP1 (study 
II). 
 
1.6 The ob/ob T2D mouse model 
The Lep ob/ob mouse is a monogenic model of obesity defective in leptin signaling; a 
commonly model used in T2D research (232). It derives from a spontaneous mutation 
of the leptin gene (233). Their weight gain begins to increase already at 2 weeks at 
which they develop hyperinsulinemia. At 4 weeks, hyperglycemia is reached, with 
blood glucose continuing to rise, peaking at 3-5 months, after which it falls when the 
mouse becomes older (234). Other metabolic derangements include hyperlipidemia, 
disturbance of temperature regulation and lower physical activity. Moreover, the 
pancreatic volume is increased, where some moderate insulin secretion is maintained 
(235); therefore, this model of diabetes is not completely representative of human T2D. 
 
1.7 Statistical analysis  
For  both ex vivo and in vitro experiments, data are presented as mean ± SEM. 
Student’s t-test was used when comparing the difference between two groups, while 
multiple comparisons were made by one-way ANOVA followed by post hoc Fisher 
LSD test or Kruskal-Wallis (Sigma Plot v. 11 software). P < 0.05 was considered 
statistically significant. 
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1.8 Ethical considerations 
All experiments were conducted according to the ‘Guide for the Care and Use of 
Laboratory Animals’ published by U.S. National Institutes of Health (NIH publication 
# 85-23, revised 1985) and approved by the regional ethics committee for animal 
experimentation 
 
2. In vivo experiments (Project 2: study III) 
2.1 The Goto-Kakizaki (GK) T2D rat model 
To determine the potential anti-stroke efficacy of the GLP-1R agonist Ex-4 in T2D, the 
GK-rat was employed. The GK-rat is a genetic animal model of T2D, originated via a 
spontaneous mutation by repetitive breeding of Wistar rats with the poorest glucose 
tolerance (236). The GK-rat is characterized by moderate hyperglycemia (12-16 mM), 
predominantly prandial in nature expected from its insulinopenic phenotype, glucose 
intolerance and defect in glucose-induced insulin secretion, whereas insulin resistance 
is a less prominent feature (237).  
 
2.2 Experimental design 
A total of 42 7–9-month-old male diabetic GK-rats were used. Before the start of the 
Ex-4/PBS treatments, baseline fasting blood glucose concentrations were measured and 
the animals were assigned to the different treatment groups so that mean blood glucose 
values were equalized. Treatment groups thus created were tested for normality using 
the D’Agostino and Pearson omnibus normality test. All rats received intraperitoneal 
injections of Ex-4 [0.1, 1 or 5 µg/kg of bw (body weight) (n=10)] or PBS (n=12) for 4 
weeks twice daily before being subjected to stroke (see below). Ex-4 and PBS 
injections were continued for another 2 or 4 weeks following the stroke before 
sacrifice. To assess neurogenesis, all rats received daily intraperitoneal injections of the 
thymidine analogue bromodeoxyuridine (BrdU; 50 mg/kg of bw) for 2 weeks following 
stroke. Rats were sacrificed for immunohistochemical analyses at 2 or 4 weeks after 
stroke. The experimental design is illustrated in Figure 3. 
 
 
 
 
 
 
 
 
 
Figure 3. Experimental design and drug administration paradigm 
 
2.3 Transient MCAO [MCA (middle cerebral artery) occlusion] 
To induce stroke in T2D GK-rats, we employed one of the most common stroke 
experimental models,  which is based on the transient unilateral middle cerebral artery 
occlusion (MCAO) (238), in which a round headed tip filament is inserted in from the 
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common carotid artery through the internal carotid artery into the circle of Willis. By so 
doing, the blood flow is blocked in one brain hemisphere. Reperfusion is achieved by 
removing the filament. This model provides reproducible MCA territory infarctions, 
involving the cortex and striatum.  Moreover, blood reperfusion simulating 
thrombolysis is allowed by withdrawing the filament at a desired time. As a result, the 
length of ischemia and the severity of the neuronal damage can be adjusted according 
to the needs of the experiments (239, 240).  
To perform MCAO, rats were anesthetized by spontaneous inhalation of 1.5% 
isofluorane through a snout-mask. Body temperature was maintained at 37–38 &C using 
a heating pad. To occlude the MCA in our experiments, the common and external 
carotid arteries were ligated, and the internal carotid artery was temporarily closed. A 
monofilament was advanced through the internal carotid artery to the origin of the 
MCA, the wound was closed and the animal was allowed to wake up and was placed in 
its cage. After 90 min of occlusion, the animals were anaesthetized again and the 
filament was withdrawn to allow for blood reperfusion. The surgeon performing the 
operation was blinded to the treatment groups. 
 
2.4 Immunocytochemistry (IHC)  
To quantify brain neurons, glia, neurogenesis and GLP-1R expression, several 
markers were assessed by IHC. Animals were deeply anesthetized and perfused 
transcardially with 4 % paraformaldehyde. The brains were extracted and submersed 
in 20 % sucrose in phosphate buffered saline overnight. 40-µm-thick coronal sections 
were cut by using a sliding microtome and stained as free-floating sections. The 
following primary antibodies were used: mouse anti-Ki67 (1:200; Novocastra; 
Sweden), a marker of cell proliferation; goat anti-DCX (doublecortin; 1:400 dilution; 
SantaCruz Biotechnology), a marker for migrating neuroblasts; mouse anti-NeuN 
(1:100; Merck Millipore; Billerica, MA), a neuronal marker; rabbit anti-Iba1 
(1:1,000; Wako Chemicals GmbH; Germany), a marker for microglia; mouse anti-
ED1 (1:200; ABd Serotec; Düsseldorf, Germany), a marker of activated microglia; rat 
anti-BrdU (1:200;Santa Cruz Biotechnology), to assess neurogenesis in combination 
with NeuN; rabbit anti-GLP-1R (1:50 dilution) (Abcam; Cambridge, MA). In the 
sections stained for GLP-1R, DAPI (4,6-diamidino-2-phenylindole) was used to 
visualize all the cells.  
Sections were incubated with primary antibodies overnight at 4 &C in phosphate 
buffer saline (PBS) containing 3 % appropriate serum and 0.25 % Triton X-100. 
Primary antibodies were detected by the use of appropriate fluorescent Cy3 
(indocarbocyanine), Cy2 (carbocyanine) (both from Jackson ImmunoResearch) or 
biotin-conjugated (Vector) secondary antibodies (1:200 dilution). Sections were 
incubated with secondary antibodies for 2 hours at room temperature (approx. 21 &C) 
in phosphate buffer containing 3 % of the appropriate serum and 0.25 % Triton X-
100. For chromogenic visualization, biotinylated secondary antibodies, avidin–boitin 
complex (ABC kit) (Vector Laboratories; Burlingame, CA) and diaminobenzidine 
were used.  
 
2.5 Tissue damage evaluation and cell quantification  
Tissue damage evaluation and cell counting were performed blindly. For tissue damage 
evaluation, the NeuN-labeled tissue sections were displayed live on the computer 
screen and the area of contralateral hemisphere and the area of the intact ipsilateral 
tissue were measured in every section containing stroke damage using the NewCast 
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(Visiopharm) software. To compensate for the stroke-induced morphological tissue 
changes, the infarct volume was calculated by subtracting the volume of remaining 
tissue in the ipsilateral hemisphere from the volume of the contralateral hemisphere. 
Immunoreactive cells were counted using either a computerized non-biased setup for 
stereology, driven by the NewCast software, or by using an Olympus BX40 
epifluorescence/light microscope. The number of neurons (NeuN) and microglia (Iba1 
and ED1) cells was quantified using the optical fractionator method (241, 242). Briefly, 
brain sections were displayed live on the computer monitor and the striatum and cortex 
delineated at low magnification. Quantifications were performed using a 100 ' oil-
immersion lens. Ten evenly spaced sections in parallel-cut series through the entire 
striatum were included. Random sampling was carried out using the counting frame; 
this was systematically moved at predefined intervals so that !200 immunoreactive 
cells were counted. The total number of cells was estimated according to the optical 
fractionator formula (241, 242). For evaluation of SVZ cell proliferation, SVZ cells 
immunoreactive for Ki67 were counted. DCX is a marker for newly produced 
neuroblasts from neurogenic brain areas and DCX-positive cells have been shown to 
migrate into the ischemic striatum (145). Hence, neuroblast production was quantified 
by counting cells positive for DCX in stroke-damaged striatum. NeuN is a ubiquitous 
nuclear marker for mature neurons. Thus, neurogenesis was assessed by counting 
NeuN/BrdU-positive cells in stroke-damaged striatum. These quantifications were 
performed in three evenly spaced (400 µm) brain sections on the side ipsilateral to 
stroke, starting at 0.7 mm anterior to Bregma. 
 
2.6 Statistical analysis  
Statistical analyses were performed using one-way or two-way ANOVA, followed by 
post hoc Bonferroni’s or Dunnet’s test (Prism 5). Differences between groups were 
considered statistically significant when P<0.05. Data are presented as mean ± SEM.  
  
2.7 Ethical considerations 
All experiments were conducted according to the ‘Guide for the Care and Use of 
Laboratory Animals’published by U.S. National Institutes of Health (NIH publication # 
85-23, revised 1985) and approved by the regional ethics committee for animal 
experimentation. 
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RESULTS 
1. Project 1 
1.1 Study I  
Pituitary adenylate cyclase-activating polypeptide counteracts the impaired adult 
neural stem cell viability induced by palmitate  
Our results show that a diabetic-like, e.g. high glucose and fat-enriched milieu, 
impaired NSC viability in a dose-dependent manner after 24 hours in vitro. We also 
show that this glucolipotoxicity was associated with an induction of apoptosis, as 
evidenced by increased and decreased cellular levels of the pro-apoptotic cleaved 
caspase-3 and of the anti-apoptotic Bcl-2 markers, respectively. We also demonstrate 
that PACAP was able to counteract the glucolipotoxic effect through the specific 
activation of PAC1 receptor, but not of VPAC1 or VPAC2 receptors. This effect was 
entirely mediated through cell protection, since NSC proliferation was not affected. 
This was further confirmed by another cell viability assay, the MTT assay. We also 
show that the neuroprotective effect of PACAP correlated with decreased apoptosis as 
measured by Bcl-2 protein levels. To study whether glucolipotoxicity impacted the 
expression of PACAP receptors in vitro and ex vivo, regulation studies of PACAP 
receptors were performed. The results of these studies reveal that PAC1 and VPAC2 
receptors are expressed by NSCs in vitro and are up-regulated under the duress of a 
glucolipotoxic milieu. In addition, we show that PAC1, VPAC1 and VPAC2 receptors 
are expressed in the SVZ/striatum ex vivo and are up-regulated in ob/ob mice (both 
young and middle-aged) versus their cognate lean litter-mates. 
In conclusion, our results indicate that a diabetic milieu -- mimicked by high glucose 
and palmitate -- decreases NSC viability. Furthermore, we show that this effect can be 
partially counteracted by PACAP through the activation of PAC1 receptors. Finally, we 
show that PACAP receptors in NSCs are regulated by a fat-enriched milieu both in 
vitro and ex vivo. 
 
1.2. Study II  
GalR3 activation promotes adult neural stem cell survival in response to a diabetic 
milieu 
In study I, we showed that high glucose and palmitate decrease NSC viability in 
conjunction with increased apoptosis. In this study, we determined whether the UPR 
signaling/ER stress was increased by high glucose and palmitate in NSCs in vitro. Our 
results show that a diabetic milieu up-regulates NSC mRNA and protein levels of the 
ER stress markers CHOP and BIP and activates the IRE1 pathway by phosphorylation 
of JNK and by enhancing the alternative splicing of XBP1. In the second part of this 
study, we aimed to determine whether the neuropeptide galanin (and by which 
receptor) could counteract a diabetic glucolipotoxicity in NSCs and -- if so -- by 
regulating apoptosis and the UPR signaling pathways. We demonstrate that galanin, via 
GalR3 activation, counteracts NSC glucolipotoxicity. This neuroprotective effect 
correlated with decreased cleaved caspase 3, indicating decreased apoptosis. 
Furthermore galanin led to decreased CHOP levels, indicating decreased ER stress.  
Finally, we studied the regulation of galanin and its receptor subtypes under diabetes-
like conditions in NSCs in vitro and in the SVZ ex vivo. Our results revealed that 
GalR3 mRNA expression levels remained unchanged in response to high glucose and 
palmitate in NSCs in vitro as well as in young pre-diabetic ob/ob mice ex vivo. 
However, GalR3 expression was strongly down-regulated in middle-aged ob/ob mice 
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in comparison with their lean littermates. In addition, galanin and its receptors (GalR1-
R2) were regulated by diabetes-like conditions in vitro and ex vivo both in young pre-
diabetic and middle-aged ob/ob mice. In summary, we show that glucolipotoxicity -- 
mimicked by a diabetic milieu -- correlates with increased ER stress as indicated by 
increased levels of CHOP, BIP, spliced form of XBP1 and phosphorylation of JNK. 
Our results also show that galanin, via GalR3 activation, can counteract this 
glucolipotoxic effect. Finally, our results show that galanin and its receptors are 
regulated by a glucolipotoxic milieu in vitro and by T2D/obesity ex vivo.  
 
2. Project 2 
2.1 Study III  
Glucagon-like peptide-1 receptor activation reduces ischemic brain damage 
following stroke in type 2 diabetic rats 
Our results show that peripheral administration of the stable GLP-1R agonist Ex-4 (for 
4 weeks before stroke and for 2 or 4 weeks after) counteracts ischemic brain damage in 
aged T2D GK rats, conferring a profound (~ 70 %) anti-stroke effect. The effect was 
dose-dependent and already statistically significant at the clinically used dose for T2D 
of 0.1 !g/kg bw. The lowest neuroprotective employed dose of Ex-4 was ineffective on 
glycemia, suggesting that the neuroprotective effect occurred independently of 
glycemia. Moreover, Ex-4 induced an arrested microglia infiltration and an increase of 
stroke-induced NSC proliferation and neuroblast formation, whereas stroke-induced 
neurogenesis was not affected. 
In conclusion, our findings indicate that the GLP-1R agonist Ex-4, at clinically relevant 
doses, confers neuroprotection in T2D rats subjected to stroke. The effect correlates 
with decreased inflammation and increased NSC activation and appears essentially 
independent of glycemic changes. 
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GENERAL DISCUSSION 
Modern lifestyle, with excessive energy intake and lowered physical activity, has 
caused an alarming increase in obesity-related pathological conditions, including T2D. 
Moreover, the incidence of neurodegenerative disorders is increasing in the Western 
world accompanying the growing number of obese and elderly people (158). Diabetic 
patients have a substantially higher risk to prematurely develop neurological 
complications such as stroke, dementia, AD, and PD [see Intro and (20, 22, 243-246)]. 
Furthermore, there is a strong co-morbidity between T2D and AD (247), sometimes 
referred to as type 3 diabetes, the reasons for which are largely unknown. Increasing 
our knowledge on the pathogenic mechanisms as to why diabetes is such a strong risk 
factor for premature CNS disorders will be required to be able to find novel drugable 
targets for therapeutic use. 
 
1. Project 1 
In T2D, there is a plethora of changes that alone or together can impair brain 
metabolism and affect neuronal viability, such as glucose toxicity, hypoglycemia, 
hyperlipidemia, hypertension, increased inflammation, oxidative stress and insulin 
resistance (40). These events may lead to damage of cerebral microvasculature and/or 
neural tissue, which in turn could influence the development of brain disorders, 
including neurodegeneration (see Intro). In addition to these more characterized factors, 
recent pre-clinical studies have shown that adult NSC populations in the SGZ and SVZ 
in the adult CNS respond to different brain diseases/disorders (143, 151, 155, 156, 
248). Furthermore, other studies have demonstrated adult neurogenesis impairment 
both in SVZ and hippocampus of obese and diabetic animal models (159, 160, 163, 
165, 166, 249-251). This suggests that dysfunctional endogenous cell replacement in 
diabetes through impaired adult neurogenesis could also play a role linking diabetes to 
its neurological complications. Consequently, pharmacological normalization of 
impaired neurogenesis in diabetes could be therapeutically useful in preventing or 
limiting diabetic CNS complications. 
 
Although some animal models of diabetes have shown neurogenesis impairment, an 
in vitro system where to study and characterize at cellular and molecular level how 
diabetes impairs NSCs has not yet been established. To understand and exploit the 
potential therapeutic use of NSCs, methodological limitations need to be overcome. 
NSCs are difficult to study in vivo; this is mainly due to the lack of specific cell 
markers of these cells (252), but also to the low number of NSCs in the SVZ and SGZ 
(253). An excellent platform to overcome these limitations is to grow adult NSCs in 
vitro (254). In this thesis, we have developed an in vitro system that has been 
previously reported under normal (non-diabetic) conditions by Bertilsson et al. (97). 
In studies I-II, we determined the effect of diabetes-like conditions on NSC viability 
in this assay. We demonstrated that a hyperglycemic (high glucose) and 
hyperlipidemic (high palmitate) milieu impairs NSC viability in a dose-dependent 
manner, and that this glucolipotoxicity correlates with increased apoptosis. Since ER 
stress may play a fundamental role in the development and pathology of certain forms 
of both diabetes and neurodegenerative diseases (66, 101), we determined whether a 
sustained activation of UPR by a diabetic milieu, leading to ER stress, correlated to 
NSC death. We demonstrated that glucolipotoxicity induced the activation of UPR 
signaling through its known pathways [e.g. PERK, IRE1 and ATF6 (101)]. 
Specifically, we showed that mRNA and protein levels of CHOP and BIP, 
phosphorylation of JNK and enhanced alternative splicing of XBP1 were increased 
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by glucolipotoxic conditions. SVZ neurogenesis has been suggested to play an 
important role in stroke recovery [see Intro and (145-147)]. Moreover, diabetic 
patients show increased stroke incidence and decreased functional recovery. Thus, 
our in vitro assay could reveal NSCs as a useful tool where to identify molecules able 
to normalize neurogenesis in diabetes; this in view to develop new potential therapies 
against stroke in diabetes. Furthermore, due to the similar features of SVZ and 
hippocampal neurogenesis (118), our results could also be of relevance to determine 
the potential role of hippocampal neurogenesis in diabetes. Impairment of 
hippocampal neurogenesis in diabetes has been suggested to play a role in decreased 
cognition (164-166). Thus, we believe that our assay could represent a useful tool to 
also progress the knowledge in these research areas.  
 
The next goal of this thesis was to identify potential molecules able to counteract loss 
of NSC viability under diabetes-like conditions. We identified PACAP (paper 1) and 
galanin (paper 2) as such molecules. Previous work has shown that both 
neuropeptides promote neurogenesis in naïve rodents (201, 203, 255) and have 
neuroprotective properties (182, 196, 199, 221, 256-258). The pleiotropic features of 
these peptides have been the main reasons of our selection. We demonstrated that 
PACAP and galanin significantly protect NSCs from glucolipotoxicity-induced cell 
death, by decreasing apoptosis. We were also interested to determine by which 
receptors the protective effect of PACAP and galanin is mediated. By taking 
advantage of several selective agonists and antagonists of both PACAP and galanin 
receptors, we showed that the protective effects of PACAP and galanin are mediated 
by PAC1 and GalR3, respectively. Further, we showed that activation of GalR3 
modulated the UPR signaling; suggesting that galanin -- via GalR3 -- can reduce NSC 
apoptosis by decreasing ER stress. Whether the attenuation of ER stress by GalR3 
activation could provide opportunities to advantage the therapeutic efforts aiming at 
preventing and treating ER-stress associated diseases is an attractive hypothesis for 
further studies.  
In view of the potential therapeutic importance of the PACAP and galanin “systems”, 
we were interested to determine PACAP and galanin receptor expression in SVZ as 
well as their potential regulation in response to diabetes-like states, both in vitro and 
ex vivo. We believe this type of information could be of potential pharmacological 
importance. While PAC1 mRNA expression in NSCs from the SVZ has been 
previously reported (201, 202), we demonstrated for the first time VPAC2 mRNA 
expression in NSCs. Further, we showed that the mRNA of each of the three PACAP 
receptors was present and up-regulated by both a glucolipotoxic milieu in vitro and in 
ob/ob T2D mice (both young and middle-aged) versus their controls. These types of 
data are difficult to interpret. However, in view of our results showing that PAC1 
counteracts NSC glucolipotoxicity, we speculate that PAC1 up-regulation might be a 
cellular attempt to prevent glucolipoapoptosis. With regard to our studies on galanin 
and its receptor subtype expression and regulation, our results show that diabetes led 
to an overall modulation of the “galanin system” both in vitro and ex vivo. To note is 
that GalR3 mRNA expression was strongly down-regulated in aged diabetic ob/ob 
mice in comparison with their non-diabetic controls. Recent data has shown that 
galanin regulates survival and differentiation of NSCs (228). We speculate that GalR3 
down-regulation in diabetes-like states could play a role in the decreased NSC 
survival and/or proliferative and differentiative capacity. As for PACAP receptor 
studies, these observations remain an interesting finding to be further investigated in 
vivo.  
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1.1 Conclusion Project 1 
 
It is estimated that around 13 % of the adult U.S. population suffers from diabetes. 
The global number of people with diabetes is projected to double by 2030 (259, 260); 
a worrying! scenario when considering the magnitude and severity of premature 
neurological complications in these individuals. Thus, we need to understand exactly 
how T2D negatively affects the brain and studies focused at the interface of 
neuroscience and diabetes research are crucial in this respect. Based on the hypothesis 
that adult neurogenesis is impaired in diabetes, and that this impairment could play a 
role in the development of the neurological complications present in diabetic patients, 
we have characterized an in vitro system in which it is possible to study this process 
under diabetes-like states. Although the results that we obtained are in vitro, and will 
have to be confirmed in vivo, our findings provide novel insights as to how a diabetic 
micro-environment has a negative impact on NSC viability. Furthermore, we show 
that PACAP and galanin protect NSCs from the toxicity of a diabetic milieu. We 
believe that these protective effects mediated by PACAP and galanin could be of 
relevance in the context of future drug development aimed at preventing and/or 
treating CNS complications in diabetes.  
 
 
 
Figure 4. Adult neurogenesis impairment in diabetes could play a role in the development of neurological 
complications. We showed that PAC1 and GalR3 activation counteracts glucolipotoxicity in adult neural 
stem by decreasing apoptosis. We also show that at least part of the protective effect mediated by GalR3 
activation occurs through the modulation of the unfolded protein response (UPR) signaling in the 
endoplasmic reticulum. The data supports a potential therapeutic development, based on increased 
neurogenesis by PAC1 and GalR3 activation, for the treatment of diabetic brain disorders. Illustration by 
Mattias Karlén. 
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2. Project 2 
As extensively discussed in the Intro, stroke is over-represented in T2D and no therapy 
based on neuroprotection is currently available clinically (20). An ideal therapy for the 
treatment of stroke in T2D would be a drug that is effective in normalizing glycemia 
(without causing hypoglycemic effects) in combination with neuroprotective properties. 
Recent studies have suggested that GLP-1R agonists indeed show this type of profile 
(see Intro). However, although preclinical data have shown neuroprotection against 
stroke mediated by the specific GLP-1R agonist Ex-4 (95, 96, 261, 262), the 
applicability of such a therapy has not been investigated in a pre-clinical setting with 
clinical relevance. Furthermore no study aimed at proving the efficacy of Ex-4 against 
stroke has been carried out in diabetic rodents.  Therefore, in study III, we aimed to 
closely mimic the way Ex-4 is used in the clinical practice against T2D by exploiting 
its neuroprotective properties against stroke. To do so, we administered clinical doses 
of Ex-4 for 4 weeks to T2D GK rats before inducing stroke by MCAO.  We then 
continued with the Ex-4 treatment (or vehicle) for 2-4 weeks thereafter. Our goal was 
to mimic the situation of a T2D patient on GLP-1R therapy who then suffers a stroke. 
Here we demonstrated that a dose of Ex-4 clinically relevant for the treatment of T2D 
showed a significant increase in neuronal survival in both striatum and cortex. 
Moreover, the effects were found to be dose-dependent with the most effective 
response at a higher dose of Ex-4 (5 !g/kg). Interestingly, our data indicated that the 
effect was independent of glycemia. We also show that the highest dose of Ex-4 
delayed pro-inflammatory microglia infiltration in the cortex, suggesting that at least 
part of the neuroprotective effect mediated by Ex-4 could occur by the regulation of 
microglia. Finally, the results show that, as expected, stroke-induced increase in the 
stem/progenitor cell proliferation. However, Ex-4 further increased the stroke-induced 
NSC proliferative response despite the fact that this increase of proliferation did not 
result in increased neurogenesis. Whether this increased proliferation NSC contributes 
to the reduction of the infarct volume and neuronal survival after stroke remains to be 
investigated.     
 
2.1 Conclusion project 2  
 
Our results show neuroprotective efficacy against stroke by Ex-4 in a T2D rat model. 
The results let us speculate that our findings could have clinical relevance for T2D 
patients who are at high risk to suffer a stroke. Diabetic patients could be kept on a 
therapy based on GLP-1R activation primarily against their diabetes (e.g. anti-
hyperglycemic), while at the same time improving recovery after stroke by limiting 
brain injury. Indeed, recent clinical results showed that diabetic patients on GLP-1R 
therapy show a better cardiovascular profile and decreased stroke compared to those on 
sulfonylurea therapy (263). The molecular mechanisms at the basis of GLP-1R-
mediated neuroprotection have been poorly investigated. Although we provided data 
showing that Ex-4 reduced microglia infiltration and increased NSC proliferation, more 
experiments are needed to precisely identify the mechanism(s) of action underlying the 
observed neuroprotection.  
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OVERALL CONCLUSIONS 
The results of this thesis provide new knowledge about a potential mechanism by 
which T2D could lead to CNS complications: by regulating adult neurogenesis. In the 
established assay described in project 1, mechanistic aspects about how diabetes can 
negatively impact adult neurogenesis could be studied. If our hypothesis will be 
validated, this assay has also the potential to be developed into a screening platform 
for the identification of drugs against brain diabetic complications. 
The results of this thesis also achieve new knowledge for the potential use of GLP-1R 
activation against stroke in diabetes. Previous data have showed GLP-1R-mediated 
neuroprotection against stroke by using experimental paradigms difficult to be 
translated to the clinical reality. Our results indicate the potential use of a GLP-1R 
activation therapy highly suitable for T2D patients suffering from a stroke. 
 
 
 
 
 
 
 
 
 
!!
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